Title: Podocytopathy with SLE: A Report of Two Cases
Authors: Hana S. Alahmari, Mansour Y. Somaily, Mohammed M. Alomair, Tariq E. Aljohani, Abdulrahman K. Alabdulsalam, Mohammed A. Omair
DOI: https://dx.doi.org/10.18535/jmscr/v7i9.41
Abstract
Background
Lupus podocytopathy is a recently recognised new entity of lupus nephritis characterised by diffuse foot process effacement with or without mesangial expansion. Glomerular proliferation and capillary wall immune deposits were inadequate in the histopathological analysis. Clinically, it is manifesting as nephrotic proteinuria in the majority of reported cases. The knowledge about the epidemiology, precipitant aetiology and choices of management are lacking. Here, we describe 2 cases presented with significant proteinuria secondary to foot process effacement with the absence of immunocomplement deposition or glomerular inflammation.
References
- Fogo AB, Kashgarian M. Diagnostic Atlas of Renal Pathology. 2016.
- Chen D, Hu W. Lupus podocytopathy: a distinct entity of lupus nephritis. J Nephrol. 2018;31(5):629-34.
- Bomback AS, Markowitz GS. Lupus Podocytopathy: A Distinct Entity. Clin J Am SocNephrol. 2016;11(4):547-8.
- Hu W, Chen Y, Wang S, Chen H, Liu Z, Zeng C, et al. Clinical-Morphological Features and Outcomes of Lupus Podocytopathy. Clin J Am SocNephrol. 2016;11(4):585-92.
- Huong DL, Papo T, Beaufils H, Wechsler B, Bletry O, Baumelou A, et al. Renal involvement in systemic lupus erythematosus. A study of 180 patients from a single center. Medicine. 1999;78(3):148-66.
- Dube GK, Markowitz GS, Radhakrishnan J, Appel GB, D'Agati VD. Minimal change disease in systemic lupus erythematosus. Clinical nephrology. 2002;57(2):120-6.
- Kraft SW, Schwartz MM, Korbet SM, Lewis EJ. Glomerular podocytopathy in patients with systemic lupus erythematosus. J Am SocNephrol. 2005;16(1):175-9.
- SF Wang YC, DQ Chen, ZZ Liu, F Xu, CH Zeng and WX Hu. Mesangial proliferative lupus nephritis with podocytopathy: a special entity of lupus nephritis. 2017.
- Cunard R, Kelly CJ. T Cells and Minimal Change Disease. Journal of the American Society of Nephrology. 2002;13(5):1409.
- Lai KW, Wei CL, Tan LK, Tan PH, Chiang GS, Lee CG, et al. Overexpression of interleukin-13 induces minimal-change-like nephropathy in rats. J Am SocNephrol. 2007;18(5):1476-85.
- Lee SJ, Borsting E, Declèves A-E, Singh P, Cunard R. Podocytes express IL-6 and lipocalin 2/ neutrophil gelatinase-associated lipocalin in lipopolysaccharide-induced acute glomerular injury. Nephron Experimental nephrology. 2013;121(3-4):e86-e96.
- WX Hu YC, H Bao, ZZ Liu, SF Wang, HT Zhang and ZH Liu. Glucocorticoid with or without additional immunosuppressant therapy for patients with lupus podocytopathy: a retrospective single-center study. 2015.
- Meyrier A. Focal and segmental glomerulosclerosis: multiple pathways are involved. Seminars in nephrology. 2011;31(4):326-32.
- Yu C-C, Fornoni A, Weins A, Hakroush S, Maiguel D, Sageshima J, et al. Abatacept in B7-1-positive proteinuric kidney disease. The New England journal of medicine. 2013;369(25):2416-23.